Heparin-Induced MSC Size Reduction for Bone Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for transplanting mesenchymal stem cells (MSC) to treat bone-related diseases face challenges, including low contribution to bone tissue formation and unsatisfactory cell quantity, as transplanted MSCs are not committed to an osteoblastic lineage and have variable transplantation properties.
Innovation Solution
Contacting MSC or MSC-derived cells with heparin or its derivatives at a concentration of at least 0.01 IU/ml in vitro or ex vivo, combined with FGF-2 and TGFβ, results in standardized, homogeneous, small-sized MSC-derived cells with improved transplantation properties, including enhanced osteogenic activity and bone formation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If MSC are transplanted without prior differentiation or commitment, then the transplantation procedure is simple, but the contribution to bone tissue formation is low
Solution Approach 1:
The patent applies preliminary action by inducing osteoblastic differentiation of MSC in vitro before transplantation. The method involves culturing MSC with osteogenic factors (such as BMP-2, BMP-7, or PTHrP) to commit cells to the osteoblastic lineage prior to administration, ensuring they are ready to contribute to bone formation upon implantation rather than requiring in vivo differentiation.
2Quantity of substance
If MSC are cultured to increase quantity, then the cell concentration is improved, but the cell size becomes variable and transplantation properties deteriorate
Solution Approach 1:
The patent applies parameter changes by optimizing culture conditions including specific growth factors, cytokines, and physical parameters (such as oxygen tension, temperature, and substrate composition) to maintain consistent cell size and morphology while achieving desired cell concentration. The method controls differentiation parameters to ensure homogeneous cell populations with standardized dimensions suitable for transplantation.
3Productivity
If MSC are differentiated to commit to osteoblastic lineage, then the bone formation capability is improved, but the cell population becomes less undifferentiated and more specialized
Solution Approach 1:
The patent applies preliminary action by performing differentiation in vitro before transplantation, allowing cells to be pre-committed to osteoblastic lineage while maintaining controlled differentiation states. This enables the cells to possess both specialized bone-forming capability and retained some plasticity for adaptation to the specific bone defect site upon transplantation.
Data Source
AI summary
The application discloses a method for obtaining MSC-derived cells with improved transplantation properties from MSC, the method comprising a cell size reduction step, wherein said cell size reduction step is characterized by contacting MSC or MSC-derived cells in vitro or ex vivo with heparin or a derivative or analogue thereof at a concentration of at least 0.01 IU/ml. The application further provides a method for obtaining mesenchymal stem cell-derived cells from mesenchymal stem cells (MSC) comprising contacting MSC in vitro or ex vivo with FGF-2, TGFβ and at least 0.01 IU/ml heparin or a derivative or analogue thereof. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof.